Imigran (Sumatriptan)

Sumatriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. This action causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, thereby reducing pain signaling in the trigeminovascular system.

The dose of Imigran is determined by the prescribing clinician. For the nasal spray, a typical regimen may involve one spray per migraine attack, with a possible second dose after at least two hours if needed, but the exact dosing schedule must be individualized by a healthcare professional.

Safety data for sumatriptan in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare provider.

To order Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imigran offers rapid intranasal delivery, which can provide faster onset of relief compared with oral tablets that require gastrointestinal absorption. Compared with other triptans, the nasal spray bypasses the stomach, making it useful for patients with nausea or vomiting during migraine attacks.

Imigran nasal spray should be stored at room temperature, below 25 °C. Keep the device in its original packaging, protect it from moisture and direct heat, and ensure the cap is securely closed when not in use.

To administer Imigran, gently blow the nose to clear the nostrils, insert the spray tip into one nostril, and press the actuator to deliver a single spray while breathing in gently. The patient may repeat the dose in the other nostril if directed by a clinician, observing the recommended interval.

Serious risks include coronary vasospasm leading to chest pain or heart attack, stroke, severe hypertension, anaphylaxis, and serotonin syndrome, especially when combined with other serotonergic medications. Patients should seek immediate medical attention if they experience chest discomfort, severe headache, visual changes, or signs of an allergic reaction.

Imigran is contraindicated in individuals with known coronary artery disease, uncontrolled hypertension, a history of stroke or hemiplegic migraine, and those currently taking MAO inhibitors or other triptans. It should also be avoided in patients with severe hepatic impairment unless specifically advised by a physician.